Helen M. Coley
Division of Biological Sciences
Faculty of Health and Medical Sciences
University of Surrey
Guildford
UK
Name/email consistency: high
- Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Coley, H.M. Methods Mol. Biol. (2010)
- Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Coley, H.M. Cancer Treat. Rev. (2008)
- The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Coley, H.M., Shotton, C.F., Kokkinos, M.I., Thomas, H. Gynecol. Oncol. (2007)
- Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity. Coley, H.M., Labeed, F.H., Thomas, H., Hughes, M.P. Biochim. Biophys. Acta (2007)
- Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Coley, H.M., Shotton, C.F., Thomas, H. Anticancer Res. (2007)
- Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Coley, H.M., Shotton, C.F., Ajose-Adeogun, A., Modjtahedi, H., Thomas, H. Biochem. Pharmacol. (2006)
- Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Coley, H.M., Verrill, M.W., Gregson, S.E., Odell, D.E., Fisher, C., Judson, I.R. Eur. J. Cancer (2000)